Parag Garhyan

1.3k total citations
34 papers, 854 citations indexed

About

Parag Garhyan is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Parag Garhyan has authored 34 papers receiving a total of 854 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 15 papers in Molecular Biology and 14 papers in Surgery. Recurrent topics in Parag Garhyan's work include Diabetes Management and Research (13 papers), Diabetes Treatment and Management (13 papers) and Pancreatic function and diabetes (13 papers). Parag Garhyan is often cited by papers focused on Diabetes Management and Research (13 papers), Diabetes Treatment and Management (13 papers) and Pancreatic function and diabetes (13 papers). Parag Garhyan collaborates with scholars based in United States, Singapore and Colombia. Parag Garhyan's co-authors include S.S.E.H. Elnashaie, Thomas A. Hardy, Christof Kazda, Haoda Fu, Mark A. Deeg, Chay Ngee Lim, Andrés Mahecha‐Botero, Melvin Prince, Cristina B. Guzmán and Sudha S. Shankar and has published in prestigious journals such as Diabetes Care, Cell Metabolism and Industrial & Engineering Chemistry Research.

In The Last Decade

Parag Garhyan

33 papers receiving 845 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Parag Garhyan United States	15	499	369	363	106	79	34	854
Francesco Micheletto Italy	9	774 1.6×	601 1.6×	156 0.4×	153 1.4×	296 3.7×	9	973
Brian Topp United States	11	380 0.8×	407 1.1×	362 1.0×	125 1.2×	212 2.7×	21	874
Ernst‐Joachim Freyse Germany	16	463 0.9×	295 0.8×	203 0.6×	97 0.9×	172 2.2×	38	774
L. Schaupp Austria	13	451 0.9×	289 0.8×	102 0.3×	60 0.6×	189 2.4×	23	720
Jakob S. Hansen Denmark	14	202 0.4×	165 0.4×	438 1.2×	383 3.6×	68 0.9×	27	993
Minzhi Liu China	18	418 0.8×	299 0.8×	357 1.0×	45 0.4×	57 0.7×	59	1.1k
Kazunori Morita Japan	15	185 0.4×	121 0.3×	70 0.2×	55 0.5×	28 0.4×	43	603
Ruifang Li‐Gao Netherlands	13	65 0.1×	71 0.2×	130 0.4×	76 0.7×	108 1.4×	46	480
Patrick C. Moore United States	10	454 0.9×	749 2.0×	447 1.2×	234 2.2×	390 4.9×	15	1.1k
Ursula Neumann Germany	16	112 0.2×	88 0.2×	164 0.5×	184 1.7×	27 0.3×	24	711

Countries citing papers authored by Parag Garhyan

Since Specialization

Citations

This map shows the geographic impact of Parag Garhyan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Parag Garhyan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Parag Garhyan more than expected).

Fields of papers citing papers by Parag Garhyan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Parag Garhyan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Parag Garhyan. The network helps show where Parag Garhyan may publish in the future.

Co-authorship network of co-authors of Parag Garhyan

This figure shows the co-authorship network connecting the top 25 collaborators of Parag Garhyan. A scholar is included among the top collaborators of Parag Garhyan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Parag Garhyan. Parag Garhyan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

James, Douglas E., et al.. (2024). Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetes. CPT Pharmacometrics & Systems Pharmacology. 13(7). 1214–1223. 1 indexed citations

Zhu, Rui, Bianca Vora, Sujatha Menon, et al.. (2023). Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective. Clinical Pharmacology & Therapeutics. 114(4). 751–767. 18 indexed citations

Bénichou, Olivier, Tamer Coşkun, Malgorzata D. Gonciarz, et al.. (2023). Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist. Cell Metabolism. 35(2). 274–286.e10. 52 indexed citations

Garhyan, Parag, Edward Pratt, Oliver Klein, et al.. (2022). Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes. Journal of Diabetes Science and Technology. 17(2). 274–282.

Xing, Yifan, et al.. (2020). Development and Verification of a Body Weight–Directed Disease Trial Model for Glucose Homeostasis. The Journal of Clinical Pharmacology. 61(2). 234–243. 2 indexed citations

Cox, Amy L., Eric D. Hawkins, Jie Xue, et al.. (2020). Insulin, Not the Preservative m-cresol, Instigates Loss of Infusion Site Patency Over Extended Durations of CSII in Diabetic Swine. Journal of Pharmaceutical Sciences. 110(3). 1418–1426. 10 indexed citations

Pörksen, Niels, Helle Linnebjerg, Parag Garhyan, et al.. (2018). Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus. Diabetes Obesity and Metabolism. 20(5). 1193–1201. 5 indexed citations

Søndergaard, Esben, Helle Linnebjerg, Parag Garhyan, et al.. (2017). Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes. Diabetes Obesity and Metabolism. 20(2). 419–426. 7 indexed citations

Kazda, Christof, Juan P. Frías, Xuewei Cui, et al.. (2017). Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 19(8). 1071–1077. 36 indexed citations

10.

Birngruber, Thomas, Niels Pörksen, Helle Linnebjerg, et al.. (2017). Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion. Diabetes Technology & Therapeutics. 19(5). 305–314. 6 indexed citations

11.

Harris, Cynthia J., Thomas Först, Tim Heise, et al.. (2017). Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8. Diabetes Technology & Therapeutics. 19(8). 463–470. 4 indexed citations

12.

Garhyan, Parag, et al.. (2016). A Comprehensive Review of Novel Drug–Disease Models in Diabetes Drug Development. Clinical Pharmacokinetics. 55(7). 769–788. 10 indexed citations

13.

Kelly, Raymond P., Parag Garhyan, Eyas Raddad, et al.. (2015). Short‐term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obesity and Metabolism. 17(4). 414–422. 92 indexed citations

14.

Detke, Holland C., Fangyi Zhao, Parag Garhyan, Janice Carlson, & David McDonnell. (2010). Dose correspondence between olanzapine long-acting injection and oral olanzapine. International Clinical Psychopharmacology. 26(1). 35–42. 23 indexed citations

15.

Elnashaie, S.S.E.H., Zhongxiang Chen, Parag Garhyan, Pradeep Prasad, & Andrés Mahecha‐Botero. (2006). Practical Implications of Bifurcation and Chaos in Chemical and Biological Reaction Engineering. International Journal of Chemical Reactor Engineering. 4(1). 10 indexed citations

16.

Garhyan, Parag, Andrés Mahecha‐Botero, & S.S.E.H. Elnashaie. (2005). Complex bifurcation/chaotic behavior of acetylcholinesterase and cholineacetyltransferase enzymes system. Applied Mathematical Modelling. 30(9). 824–853. 9 indexed citations

17.

Mahecha‐Botero, Andrés, Parag Garhyan, & S.S.E.H. Elnashaie. (2005). Bifurcation, stabilization, and ethanol productivity enhancement for a membrane fermentor. Mathematical and Computer Modelling. 41(4-5). 391–406. 9 indexed citations

18.

Mahecha‐Botero, Andrés, Parag Garhyan, & S.S.E.H. Elnashaie. (2005). Non-linear characteristics of a membrane fermentor for ethanol production and their implications. Nonlinear Analysis Real World Applications. 7(3). 432–457. 24 indexed citations

19.

Garhyan, Parag & S.S.E.H. Elnashaie. (2004). Bifurcation analysis of two continuous membrane fermentor configurations for producing ethanol. Chemical Engineering Science. 59(15). 3235–3268. 20 indexed citations

20.

Garhyan, Parag & S.S.E.H. Elnashaie. (2004). Utilization of mathematical models to investigate the bifurcation and chaotic behavior of ethanol fermentors. Mathematical and Computer Modelling. 39(4-5). 381–427. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact